卡培他滨维持治疗联合最佳支持治疗对比单用最佳支持治疗对新诊断转移性鼻咽癌接受诱导化疗后患者无进展生存期的影响:一项3期随机临床试验
这项3期随机临床试验在中山大学肿瘤防治中心纳入104例新诊断转移性鼻咽癌患者,患者在接受4至6周期紫杉醇、顺铂和卡培他滨诱导化疗后达到疾病控制,随机接受卡培他滨维持治疗联合最佳支持治疗或单用最佳支持治疗。结果显示卡培他滨维持治疗组中位无进展生存期显著优于单用最佳支持治疗组,且毒性可管理。
要点
- 卡培他滨维持治疗组中位无进展生存期为35.9个月,单用最佳支持治疗组为8.2个月,风险比为0.44。
- 卡培他滨维持治疗组客观缓解率为25.0%,单用最佳支持治疗组为11.5%。
- 维持治疗期间最常见的3级或4级不良事件为贫血(6/50,12.0%)和手足综合征(5/50,10.0%),维持组无治疗相关死亡。
核心结论
- 在新诊断转移性鼻咽癌接受含卡培他滨诱导化疗后达到疾病控制的患者中,卡培他滨维持治疗显著改善无进展生存期,且毒性可管理。
研究设计与样本
- 这项3期随机临床试验在中山大学肿瘤防治中心开展,纳入104例新诊断转移性鼻咽癌患者,患者在接受4至6周期紫杉醇、顺铂和卡培他滨诱导化疗后达到疾病控制,按1:1随机分组,所有疗效分析在意向治疗人群中进行。
主要发现
- 中位随访33.8个月(IQR 22.9-50.7个月)期间,卡培他滨维持治疗组有23例(44.2%)进展或死亡事件,单用最佳支持治疗组有37例(71.2%)进展或死亡事件。
- 卡培他滨维持治疗组中位无进展生存期为35.9个月(95%CI 20.5个月-未达到),单用最佳支持治疗组为8.2个月(95%CI 6.4-10.0个月),风险比为0.44(95%CI 0.26-0.74;P=0.002)。
- 卡培他滨维持治疗组客观缓解率为25.0%(13例),单用最佳支持治疗组为11.5%(6例);卡培他滨维持治疗组中位缓解持续时间为40.0个月(95%CI 未达到-未达到),单用最佳支持治疗组为13.2个月(95%CI 9.9-16.5个月)。
- 维持治疗期间最常见的3级或4级不良事件为贫血(6/50,12.0%)、手足综合征(5/50,10.0%)、恶心呕吐(3/50,6.0%)、乏力(2/50,4.0%)和黏膜炎(2/50,4.0%);维持治疗组无死亡事件被认为与治疗相关。
关键数值与推荐
- 卡培他滨维持治疗方案为1000 mg/m2口服,每日两次,第1至14天给药,每3周重复一次,联合最佳支持治疗。
- 主要终点为无进展生存期,次要终点包括客观缓解率、缓解持续时间、总生存期和安全性。
临床怎么用
- 对于新诊断转移性鼻咽癌接受含卡培他滨诱导化疗后达到疾病控制的患者,卡培他滨维持治疗联合最佳支持治疗可显著改善无进展生存期,且毒性可管理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Capecitabine maintenance therapy improves survival outcomes in various cancer types, but data are limited on the efficacy and safety of capecitabine maintenance therapy in metastatic nasopharyngeal carcinoma (NPC). OBJECTIVE: To investigate the efficacy and safety of capecitabine maintenance therapy in metastatic NPC. DESIGN, SETTING, AND PARTICIPANTS: This randomized phase 3 clinical trial was conducted at Sun Yat-sen University Cancer Center from May 16, 2015, to January 9, 2020, among 104 patients with newly diagnosed metastatic NPC who had achieved disease control after 4 to 6 cycles of induction chemotherapy with paclitaxel, cisplatin, and capecitabine. The final follow-up date was May 30, 2021. All efficacy analyses were conducted in the intention-to-treat population. INTERVENTIONS: Eligible patients were randomly assigned (1:1) to receive either capecitabine maintenance therapy (1000 mg/m2 orally twice daily on days 1-14) every 3 weeks plus best supportive care (BSC) (capecitabine maintenance group) or BSC alone after 4 to 6 cycles of induction chemotherapy. MAIN OUTCOMES AND MEASURES: Progression-free survival (PFS). Secondary end points were objective response rate, duration of response, overall survival, and safety. RESULTS: This study included 104 patients (84 men [80.8%]; median age, 47 years [IQR, 38-54 years]), with 52 assigned to the capecitabine maintenance group and 52 assigned to the BSC group. After a median follow-up of 33.8 months (IQR, 22.9-50.7 months), there were 23 events (44.2%) of progression or death in the capecitabine maintenance group and 37 events (71.2%) of progression or death in the BSC group. Median PFS survival was significantly higher in the capecitabine maintenance group (35.9 months [95% CI, 20.5 months-not reached]) than in the BSC group (8.2 months [95% CI, 6.4-10.0 months]), with a hazard ratio of 0.44 (95% CI, 0.26-0.74; P = .002). Higher objective response rates and longer median duration of response were observed in the capecitabine maintenance group (25.0%; 40.0 months) compared with the BSC group (objective response rate, 25.0% [n = 13] vs 11.5% [n = 6]; and median duration of response, 40.0 months [95% CI, not reached-not reached] vs 13.2 months [95% CI, 9.9-16.5 months]). The most common grade 3 or 4 adverse events during maintenance therapy were anemia (6 of 50 [12.0%]), hand-foot syndrome (5 of 50 [10.0%]), nausea and vomiting (3 of 50 [6.0%]), fatigue (2 of 50 [4.0%]), and mucositis (2 of 50 [4.0%]). No deaths in the maintenance group were deemed treatment-related. CONCLUSIONS AND RELEVANCE: In this phase 3 randomized clinical trial, capecitabine maintenance therapy significantly improved PFS for patients with newly diagnosed metastatic NPC who achieved disease control after capecitabine-containing induction chemotherapy. Capecitabine exhibited manageable toxic effects. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02460419.
引用
- Liu GY, Li WZ, Wang DS, et al. Effect of Capecitabine Maintenance Therapy Plus Best Supportive Care vs Best Supportive Care Alone on Progression-Free Survival Among Patients With Newly Diagnosed Metastatic Nasopharyngeal Carcinoma Who Had Received Induction Chemotherapy: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2022. PMID: 35175316. doi:10.1001/jamaoncol.2021.7366
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。